A Phase 2 Multi-arm, Open Label Study to Assess the Safety and Efficacy of EP0057 in Combination With Olaparib in Defined Populations of Patients With Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer
Latest Information Update: 13 Jun 2023
At a glance
Most Recent Events
- 09 Jun 2023 Status changed from not yet recruiting to withdrawn prior to enrolment. Reason the study was stopped: Futility analysis decision to terminate EP0057 compound and all Ellipses sponsored studies involving EP0057.
- 01 Nov 2022 Planned initiation date changed from 1 Jul 2022 to 1 Apr 2023.
- 14 Jun 2022 New trial record